NXTCL is allocated approximately SEK 12.9 million through redemption of warrants
During the period 23rd August – 13th September 2018, holders of series TO 1 warrants in NextCell Pharma AB ("NXTCL") have been able to subscribe for shares on the basis of their warrants. In total 2 720 931 warrants of series TO 1 were exercised, which means a subscription rate of 95.11 percent. NXTCL is therefore allocated approx. SEK 13.6 million before issue costs, which are estimated to amount to approx. SEK 0.7 million.
CEO Mathias Svahn comments
"I would like to thank all of those who have shown - and continue to show - their interest and trust in the stem cell company NXTCL. We have just completed the treatment of the last patient in the high dose cohort and provided that nothing unexpected happens, we hope to start the second part of the study in Q4 2018. The funds we will now receive will be sufficient to finance the completion of the clinical trial with ProTrans and we plan to present the first study results by the end of 2019.
Series warrants TO 1
A total of 2 720 931 series TO 1 warrants were exercised, which means that 2 720 931 new shares will be registered with the Swedish Companies Registration Office. NXTCL is therefore allocated approx. SEK 13.6 million before issue costs, which are estimated to amount to approx. SEK 0.7 million.
Number of shares and share capital
When the new shares have been registered with the Swedish Companies Registration Office, the number of shares in NXTCL will amount to 11 226 356 and the share capital will amount to approximately 2 301 403 SEK.
Financial adviser and issuing agent
Sedermera Fondkommission is the financial advisor to NXTCL for the subscription period of the series TO 1 warrants.
For more information regarding the subscription of series TO 1 warrants, please contact:
Phone: 040-615 14 10
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 17th of September 2018.
Stay up to date with the latest development in NextCell Pharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Leo Groenewegen, CFO
Phone: 08-735 5595
About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.